Singapore-US & Brazil collaboration to advance microbiome-informed therapeutic discovery

Updated: 4 hours ago
Nintx and Minutia.AI are pleased to announce their ongoing scientific collaboration, which brings together highly complementary capabilities to advance microbiome-based therapeutic discovery

Understanding the gut microbiome requires more than knowing which microorganisms are present. It requires understanding how they function within a community, interact with the host and respond to intervention.
Through xGIbiomics® and its cellular research capabilities, Nintx integrates gastrointestinal fermentation, microbiome analysis, intestinal-barrier models, and experimental validation to investigate natural products and translate scientific findings into potential therapeutic solutions.
Minutia.AI contributes its gut twin™, integrating systems biology, causal discovery and computational modelling of multiomics data to examine microbes’ interactions and generate causal hypotheses for experimental testing.
Together, we are developing an iterative discovery approach in which computational models help prioritize promising interventions, experimental studies test their biological effects and the resulting data continuously improve future predictions.
Our shared goal is to better understand how natural products influence the microbiome and its relationship with the host, and use that knowledge to advance microbiome-informed therapeutic discovery.
To have access to the full content, check us out on LinkedIn.



